FindTrial
Sign In

Response to treatment in patients with chronic hepatitis C genotype and drug sovodak newly diagnosed patients with previous treatment failure

Compare the response to treatment in patients with newly diagnosed chronic hepatitis C (genotype ? ) and patients without any response to previous treatments , with combination of sofosbuvir-daklatsvir

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201702016388N7
Enrollment
50
Registered
2017-04-08
Start date
2016-11-12
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C. Chronic viral hepatitis C

Interventions

Intervention 1: In the intervention group, patients with hepatitis C who were treated with other drugs and were facing defeat, Drug treatment, Sofosbuvir daily at a dose of 400 mg daily oral doses of
Treatment - Drugs
In the intervention group, patients with hepatitis C who were treated with other drugs and were facing defeat, Drug treatment, Sofosbuvir daily at a dose of 400 mg daily oral doses of 60 mg Daklinza o
In the control group of patients with hepatitis C who have not previously undergone any treatment, Drug treatment, Sofosbuvir daily at a dose of 400 mg daily oral doses of 60 mg Daklinza oral pharmace

Sponsors

Vice Chancellor for Research of Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: People with HCV genotype HCV RNA in a headline above or positive? People who have detectable HCV RNA titers after previous treatment failure and relapse patients. Exclusion criteria: People who sovodak therapy to stop for any reason? People infected with virus (HIV) concurrently? There is no reason other than HCV patients with chronic hepatitis? People with hepatitis B concurrently? People who have undergone liver transplantation recently? People who have low life expectancy? There is no assurance that the cut intravenous drug users inject drugs? Patients who received Amiodarone in the last 6 months? Women who are pregnant or plan to become pregnant or are breastfeeding? Those who have allergies to Lactose (sovodak with Lactose).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Hepatitis C RNA. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Test.—

Secondary

MeasureTime frame
Liver Echogenicity. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: paraclinical tests.;Albumin. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Test.;Portal vein diameter. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Sonography.;Splenic vein diameter. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Sonography.;Spleen size. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Sonography.;INR. Timepoint: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment. Method of measurement: Test.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Hosein Somi

Tabriz University of Medical Sciences

somimh@tbzmed.ac.ir+98 41333347554

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026